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BACKGROUND
Multiparametric magnetic resonance imaging (MRI), with or without targeted bi-
opsy, is an alternative to standard transrectal ultrasonography–guided biopsy for 
prostate-cancer detection in men with a raised prostate-specific antigen level who have 
not undergone biopsy. However, comparative evidence is limited.
METHODS
In a multicenter, randomized, noninferiority trial, we assigned men with a clinical 
suspicion of prostate cancer who had not undergone biopsy previously to undergo 
MRI, with or without targeted biopsy, or standard transrectal ultrasonography–
guided biopsy. Men in the MRI-targeted biopsy group underwent a targeted biopsy 
(without standard biopsy cores) if the MRI was suggestive of prostate cancer; men 
whose MRI results were not suggestive of prostate cancer were not offered biopsy. 
Standard biopsy was a 10-to-12–core, transrectal ultrasonography–guided biopsy. 
The primary outcome was the proportion of men who received a diagnosis of clini-
cally significant cancer. Secondary outcomes included the proportion of men who 
received a diagnosis of clinically insignificant cancer.
RESULTS
A total of 500 men underwent randomization. In the MRI-targeted biopsy group, 
71 of 252 men (28%) had MRI results that were not suggestive of prostate cancer, 
so they did not undergo biopsy. Clinically significant cancer was detected in 95 men 
(38%) in the MRI-targeted biopsy group, as compared with 64 of 248 (26%) in the 
standard-biopsy group (adjusted difference, 12 percentage points; 95% confidence 
interval [CI], 4 to 20; P = 0.005). MRI, with or without targeted biopsy, was nonin-
ferior to standard biopsy, and the 95% confidence interval indicated the superior-
ity of this strategy over standard biopsy. Fewer men in the MRI-targeted biopsy 
group than in the standard-biopsy group received a diagnosis of clinically insignifi-
cant cancer (adjusted difference, −13 percentage points; 95% CI, −19 to −7; P<0.001).
CONCLUSIONS
The use of risk assessment with MRI before biopsy and MRI-targeted biopsy was 
superior to standard transrectal ultrasonography–guided biopsy in men at clinical 
risk for prostate cancer who had not undergone biopsy previously. (Funded by the 
National Institute for Health Research and the European Association of Urology Re-
search Foundation; PRECISION ClinicalTrials.gov number, NCT02380027.)
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Men with a clinical suspicion of prostate cancer on the basis of an ele-vated prostate-specific antigen (PSA) 
level or an abnormal digital rectal examination 
are typically offered a standard transrectal ultra-
sonography–guided biopsy of the prostate during 
which 10 to 12 cores are obtained. This approach 
is associated with the underdetection of higher-
grade (clinically significant) prostate cancers and 
the overdetection of low-grade (clinically insig-
nificant) cancers.1 Despite randomized trials 
showing that men with clinically insignificant 
cancer do not benefit from treatment,2,3 its iden-
tification still results in the overtreatment of 
some men. Some men will receive radical treat-
ment that has side effects,4,5 and others will 
undergo active surveillance with repeated as-
sessment over time that has costs for patients 
and health care systems.6,7
An alternative diagnostic pathway in men 
with a clinical suspicion of prostate cancer in-
volves multiparametric magnetic resonance im-
aging (MRI). With better standardization of the 
conduct and reporting of multiparametric MRI, 
the ability to detect clinically significant cancer 
and to rule it out has improved over the past 
decade.1,8,9 Multiparametric MRI could be used 
as a triage test to avoid a biopsy if the results 
were negative,1 whereas positive results could be 
used for targeting abnormal areas in the pros-
tate during biopsy.10,11
In single-center studies, the approach of ob-
taining MRI-targeted biopsy cores alone, with-
out performing standard biopsies, has shown 
similar or higher rates of detection of clinically 
significant cancer12-15 and lower rates of detection 
of clinically insignificant cancer15 than standard 
biopsy. We compared MRI-targeted biopsy with 
standard transrectal ultrasonography–guided bi-
opsy in a pragmatic, multicenter, randomized trial. 
The PRECISION (Prostate Evaluation for Clini-
cally Important Disease: Sampling Using Image 
Guidance or Not?) trial aimed to evaluate pro-
spectively whether multiparametric MRI, with 
targeted biopsy in the presence of an abnormal 
lesion, was noninferior to standard transrectal 
ultrasonography–guided biopsy in the detection 
of clinically significant prostate cancer in men 
with a clinical suspicion of prostate cancer who 
had not undergone biopsy of the prostate previ-
ously.
Me thods
Trial Design
We conducted this multicenter, randomized, 
noninferiority trial at 25 centers in 11 countries 
(Table S1 in the Supplementary Appendix, avail-
able with the full text of this article at NEJM.org). 
Men who provided written informed consent 
were randomly assigned in a 1:1 ratio to either 
the MRI-targeted biopsy group or the standard-
biopsy group (Fig. S1 in the Supplementary Ap-
pendix). The assignment sequence used computer-
generated, randomly permuted blocks of unequal 
size, stratified according to center. Group as-
signments were revealed by the Web-based sys-
tem once a participant had been assessed as eli-
gible and had provided written informed consent.
The full trial protocol, available at NEJM.org, 
has been published previously16 and was ap-
proved by the ethics review board at each par-
ticipating institution. The trial was monitored by 
an independent trial steering committee and 
data and safety monitoring committee. The trial 
was designed by the Standards of Reporting for 
MRI-Targeted Biopsy Studies (START) working 
group,10 and final decisions were made by the 
first author and the last two authors. Data were 
gathered by the trial team members who are 
listed in Section S1 in the Supplementary Ap-
pendix. One author analyzed the data, and the 
analysis was independently verified by another 
author. The authors assume responsibility for 
the accuracy and completeness of the data and 
analyses and for the adherence of the trial to the 
protocol. The first draft of the manuscript was 
written by the first author.
No commercial entity was involved in the 
trial. The trial was funded by the National Insti-
tute for Health Research and the European As-
sociation of Urology Research Foundation, with 
trial governance from University College London. 
The funders had no role in the protocol develop-
ment, data analysis or interpretation, or manu-
script preparation.
Participants
Participants were recruited in outpatient clinics 
and were eligible for enrollment if they had not 
undergone biopsy of the prostate previously and 
had been referred with a clinical suspicion of 
prostate cancer on the basis of an elevated PSA 
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level, an abnormal digital rectal examination, or 
both (Table S2 in the Supplementary Appendix). 
Participants were required to have a PSA level of 
20 ng per milliliter or less, to have results on 
digital rectal examination that did not suggest 
extracapsular disease, and to be suitable candi-
dates for biopsy of the prostate and for MRI.
MRI and MRI-Targeted Biopsy
Multiparametric MRI was performed with the 
use of a 1.5-T or 3.0-T scanner with a pelvic 
phased-array coil, with or without an endorectal 
coil (Table S3 in the Supplementary Appendix). 
T2-weighted, diffusion-weighted, and dynamic 
contrast-enhanced sequences were acquired ac-
cording to minimum standards that have been 
set by consensus guidelines.8 Areas on the mul-
tiparametric MRI that were suggestive of pros-
tate cancer were categorized by a local radiolo-
gist according to the Prostate Imaging–Reporting 
and Data System, version 2 (PI-RADS v2),9 on a 
scale from 1 to 5, with higher numbers indicat-
ing a greater likelihood of clinically significant 
cancer. Table S4 in the Supplementary Appendix 
provides details regarding the experience of the 
clinicians who took part in the trial.
Men who had a positive result on the multi-
parametric MRI — that is, in whom an area with 
a score of 3 (equivocal regarding the likelihood 
of prostate cancer), 4 (likely to be prostate can-
cer), or 5 (highly likely to be prostate cancer) 
was identified — underwent MRI-targeted bi-
opsy with the use of real-time ultrasonographic 
guidance. A maximum of three areas that were 
suggestive of prostate cancer were permitted to 
be chosen for targeted biopsy, with a maximum 
of 4 biopsy cores obtained per area, resulting in 
a maximum of 12 biopsy cores obtained per 
participant. MRI-targeted biopsy registration (i.e., 
matching of the image of the target on MRI with 
the real-time image of the prostate during bi-
opsy) could be performed by means of visual 
registration or software-assisted registration 
(also known as MRI–ultrasonographic fusion)10 
and could be carried out through the transrectal 
or transperineal route, according to local exper-
tise (Table S5 in the Supplementary Appendix). 
In the absence of abnormal areas on the multi-
parametric MRI (i.e., a negative result, with a 
score of 1 or 2), the participant was not offered 
a protocol biopsy.
Standard Transrectal Ultrasonography–
Guided Biopsy
Biopsy was carried out by experienced operators 
who used a standard transrectal technique. A to-
tal of 10 to 12 biopsy cores were obtained from 
the peripheral zone of the prostate at the base, 
mid gland, and apex.17
Participant-Reported Outcome Measures
Participant-reported questionnaires were used to 
collect data about intervention-specific side effects 
immediately and at 30 days after biopsy and after 
MRI.16,18 Health-related quality of life was as-
sessed with the use of the EuroQol–5 Dimension 
Self-Report Questionnaire at baseline, 24 hours 
after the intervention, and 30 days after the in-
tervention.19-21
Outcomes
The primary outcome was the proportion of men 
with clinically significant cancer, defined as the 
presence of a single biopsy core indicating dis-
ease of Gleason score 3+4 (Gleason sum of 7) or 
greater (the Gleason score is composed of a pri-
mary [most predominant] grade plus a secondary 
[highest nonpredominant] grade; the range for a 
primary or secondary grade is from 3 to 5, with 
the Gleason sum ranging from 6 to 10, and with 
higher scores indicating a more aggressive form 
of prostate cancer). Secondary outcomes includ-
ed the proportion of men with clinically insig-
nificant cancer (Gleason score 3+3), the propor-
tion of men in the MRI-targeted biopsy group 
who did not undergo biopsy, and the proportion 
of men with adverse events after the interven-
tion. All the secondary outcomes are listed in Table 
S6 in the Supplementary Appendix. Outcomes were 
reported according to the START guidelines,10 
which are the consensus criteria for reporting 
studies of MRI-targeted prostate biopsies.
Follow-up
Participants were followed until the visit at which 
their treatment decisions were made or until their 
30-day postintervention questionnaires were 
completed, whichever was later. Participants who 
underwent further diagnostic tests as a result of 
the outcome of the treatment-decision visit were 
additionally followed until after the results of the 
further investigation were made available and re-
corded. These participants included men who 
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had negative test results in either the standard-
biopsy group or the MRI-targeted biopsy group 
and underwent additional testing. Participants 
who had negative test results in either group at 
the end of the trial period returned to standard-
care monitoring at each center, which typically 
involved surveillance of the PSA level. Partici-
pants who underwent radical prostatectomy on 
the basis of their treatment decision were also 
followed until the pathological testing results of 
their radical prostatectomy were available. Par-
ticipants provided written informed consent for 
long-term follow-up as part of future studies 
involving additional contact from the trial center 
and linkage to national databases.
Quality Control
Uroradiologists and pathologists at the coordi-
nating center, who were unaware of the results 
of the original reports, reviewed 25% of the mul-
tiparametric MRIs and 15% of the original patho-
logical specimens. These MRIs and specimens 
had been chosen at random from participants at 
every site.
Statistical Analysis
Using a noninferiority margin of 5 percentage 
points that was agreed on at an expert consen-
sus group meeting10 and a one-sided alpha level 
of 2.5%, we calculated that the randomization of 
422 men would provide the trial with 90% 
power to show the noninferiority of MRI, with 
or without targeted biopsy, to standard biopsy, 
assuming a detection rate of clinically signifi-
cant cancer of 40% in the group that underwent 
MRI, with or without targeted biopsy, and 30% 
in the standard-biopsy group. This sample size 
was increased to 470 to allow for a 10% rate of 
withdrawal and loss to follow-up. Detailed justi-
fication of the sample size is provided in the 
protocol.16
The statistical analysis plan was prespecified 
and approved by the data and safety monitoring 
committee before the analysis of any data. For 
the primary outcome, if the lower boundary of 
the two-sided 95% confidence interval for the 
difference in the rates of detection of clinically 
significant cancer in the MRI-targeted biopsy 
group relative to the standard-biopsy group was 
greater than −5 percentage points, then MRI, 
with or without targeted biopsy, would be 
deemed to be noninferior. Furthermore, if the 
lower boundary was greater than zero, superior-
ity would be claimed. The difference was esti-
mated with the use of a generalized linear mixed 
model (with the use of an identity link function 
with a binomial distribution) that included trial 
center as a random effect.
All the participants who underwent random-
ization were included in the primary intention-
to-treat analysis. Analyses were repeated in the 
modified intention-to-treat population and the 
per-protocol population as sensitivity analyses 
(Table S7A, S7B, and S7C in the Supplementary 
Appendix). The modified intention-to-treat anal-
ysis excluded participants who did not complete 
a diagnostic test strategy; this analysis was car-
ried out to prevent unequal withdrawal in the 
two groups from contributing to a difference 
between the groups. The per-protocol analysis 
included only men who underwent the randomly 
assigned testing procedure as specified in the 
protocol; this analysis was carried out because 
this was a noninferiority trial, so a per-protocol 
analysis would reduce the chance of biasing the 
result toward the null. If, after participants had 
undergone the trial test procedures, further tests 
provided different information about the pres-
ence of cancer, no adjustment was made to the 
analyses of the primary and secondary out-
comes. A post hoc Bonferroni correction was 
used to adjust for three secondary outcomes 
(proportion of men with clinically insignificant 
cancer, maximum cancer core length, and health-
related quality of life), with a two-sided P value 
of less than 0.017 considered to indicate statisti-
cal significance. The methods of analysis of the 
other outcomes are described in Section S2 in 
the Supplementary Appendix.
R esult s
Trial Population
From February 2016 through August 2017, a to-
tal of 500 participants underwent randomization 
at 23 of the 25 sites, with 252 participants being 
assigned to the MRI-targeted biopsy group and 
248 to the standard-biopsy group (Fig. 1, and 
Table S1 in the Supplementary Appendix). The 
characteristics of the participants at baseline 
were similar in the two groups (Table 1).
A total of 71 of 252 participants (28%) in the 
MRI-targeted biopsy group had a result on mul-
tiparametric MRI that was not suggestive of 
prostate cancer (PI-RADS v2 score, ≤2), and so 
they did not undergo biopsy. Among the partici-
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pants with a positive result on multiparametric 
MRI, 51 of 175 (29%) had a PI-RADS v2 score of 
3, 70 (40%) had a score of 4, and 54 (31%) had 
a score of 5 (Table S8 in the Supplementary Ap-
pendix). The remaining 6 men did not complete 
the MRI assessment (Fig. 1). Among the partici-
pants who underwent biopsy, a median of 4 bi-
opsy cores were obtained in the MRI-targeted 
biopsy group, as compared with a median of 12 
cores in the standard-biopsy group (Table S9 in 
the Supplementary Appendix).
Outcomes
Clinically significant cancer was detected in 95 
men (38%) in the MRI-targeted biopsy group, as 
compared with 64 (26%) in the standard-biopsy 
group (adjusted difference, 12 percentage points; 
95% confidence interval [CI], 4 to 20; P = 0.005) 
(Table 2). The lower boundary of the 95% confi-
dence interval for the difference was greater 
than −5 percentage points, so MRI, with or 
without targeted biopsy, was deemed to be non-
inferior to standard transrectal ultrasonogra-
phy–guided biopsy in the detection of clinically 
significant cancer. Furthermore, the 95% confi-
dence interval showed the superiority of MRI, 
with or without targeted biopsy, over transrectal 
ultrasonography–guided biopsy. The results 
were consistent in the modified intention-to-
treat and per-protocol populations (Fig. 2).
Fewer participants received a diagnosis of 
clinically insignificant cancer in the MRI-target-
ed biopsy group than in the standard-biopsy 
group (23 men [9%] vs. 55 [22%]; adjusted dif-
ference, −13 percentage points; 95% CI, −19 to 
−7; P<0.001). In men with cancer, the mean 
maximum cancer core length was 7.8 mm in the 
MRI-targeted biopsy group and 6.5 mm in the 
standard-biopsy group (adjusted mean differ-
ence, 1.0 mm; 95% CI, 0.0 to 2.1; P = 0.053). In-
terpretations of the results for these secondary 
outcomes were unchanged by post hoc Bonfer-
roni correction (see Section S3 in the Supple-
mentary Appendix).
A greater percentage of cores were positive 
for cancer in the MRI-targeted biopsy group (422 
of 967 cores [44%]) than in the standard-biop-
sy group (515 of 2788 [18%]). Among men with 
a positive result on MRI, the percentage of men 
with clinically significant cancer was highest 
among participants with a PI-RADS v2 score of 
5 (83%), followed by those with a score of 4 
(60%) and those with a score of 3 (12%). Con-
Figure 1. Enrollment, Randomization, and Follow-up of the Participants.
Men who were randomly assigned to the magnetic resonance imaging 
(MRI)–targeted biopsy group underwent MRI. If the MRI revealed results 
that were suggestive of prostate cancer, the participant underwent a target-
ed biopsy; men whose MRI results were not suggestive of prostate cancer 
were not offered biopsy. Men who were assigned to the standard-biopsy 
group underwent standard transrectal ultrasonography–guided biopsy. 
PSA denotes prostate-specific antigen.
500 Underwent randomization
877 Participants were assessed
for eligibility
377 Were excluded before
randomization
148 Did not meet inclusion
criteria
193 Declined to participate
36 Had other reason
252 Were assigned to undergo MRI
with or without targeted biopsy
240 Underwent assigned intervention
12 Did not undergo assigned
intervention
1 Did not want further investi-
gation
6 Had abnormal MRI, but did
not undergo targeted biopsy
5 Could not undergo MRI
248 Were assigned to undergo standard
biopsy
228 Underwent assigned intervention
20 Did not undergo assigned
intervention
6 Preferred PSA surveillance
6 Did not want further investi-
gation
1 Was lost to follow-up (left
recruiting site)
1 Underwent transperineal
template biopsy
6 Underwent MRI
2 Had decision made by
clinician owing to medical
risk associated with imme-
diate standard biopsy
4 Preferred MRI
252 Were included in the intention-
to-treat analysis
245 Were included in the modified
intention-to-treat analysis
7 Did not complete diagnostic
test strategy
235 Were included in the per-protocol
analysis
17 Were excluded
12 Did not undergo assigned
intervention
2 Underwent MRI without the
use of contrast material
1 Did not undergo biopsy of
lesion found on MRI
1 Underwent standard biopsy
and targeted biopsy
1 Underwent transperineal
template biopsy and
targeted biopsy
248 Were included in the intention-
to-treat analysis
235 Were included in the modified
intention-to-treat analysis
13 Did not complete diagnostic
test strategy
227 Were included in the per-protocol
analysis
21 Were excluded
20 Did not undergo assigned
intervention
1 Had 15 standard-biopsy cores
obtained
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versely, the percentage of men without cancer 
was highest among participants with a PI-RADS 
v2 score of 3 (67%), followed by those with a 
score of 4 (31%) and those with a score of 5 (6%) 
(Fig. 3).
Quality of Life and Safety
Health-related quality of life at 24 hours and at 30 
days after the intervention did not differ signifi-
cantly between the MRI-targeted biopsy group 
and the standard-biopsy group. The intervention 
was associated with similar results regarding im-
mediate postintervention discomfort and pain in 
the two groups. The participant-reported compli-
cations at 30 days were less frequent in the MRI-
targeted biopsy group than in the standard-biopsy 
group, including events of blood in the urine 
(30% vs. 63%), blood in the semen (32% vs. 60%), 
pain at the site of the procedure (13% vs. 23%), 
rectal bleeding (14% vs. 22%), and erectile dys-
function (11% vs. 16%). These findings reflected 
the lower percentage of men undergoing biopsy 
and fewer biopsy cores obtained in the MRI-tar-
geted biopsy group than in the standard-biopsy 
group. A total of 2% of the men in the MRI-
targeted biopsy group and 2% in the standard-
biopsy group had serious adverse events. Details 
regarding health-related quality-of-life scores, 
participant-reported complications, and adverse 
events are provided in Tables S10 through S12 in 
the Supplementary Appendix.
Further Diagnostic Testing
After the discussion of the test results with each 
participant, more men in the standard-biopsy 
group (39 men [16%]) than in the MRI-targeted 
biopsy group (7 [3%]) underwent further diag-
nostic tests. Of the 39 further diagnostic tests 
that were performed in the standard-biopsy 
group, 38 (in 15% of the participants in the 
group) were diagnostic multiparametric MRIs 
that were carried out in men with negative re-
sults on the transrectal ultrasonography–guided 
biopsy. In the MRI-targeted biopsy group, only 
3 participants (1%) with negative results on 
MRI subsequently underwent standard trans-
rectal ultrasonography–guided biopsy. More men 
who underwent MRI-targeted biopsy (104 men 
[41%]) than men who underwent standard trans-
rectal ultrasonography–guided biopsy (74 [30%]) 
adopted a strategy of monitoring of the PSA 
level, although the percentage of men undergo-
ing active surveillance or radical treatment was 
similar in the two groups.
Among the participants who underwent fur-
ther biopsy, clinically significant cancer was 
detected in none of the 4 men in the MRI-target-
ed biopsy group and in 3 of 9 men (33%) in the 
standard-biopsy group. Of the 71 men with 
negative results on MRI and no biopsy, 3 (4%) 
were discharged, 62 (87%) were referred for 
monitoring of the PSA level, 3 (4%) underwent 
further prostate biopsy (all had negative results), 
1 (1%) underwent an additional multiparametric 
MRI, and 2 (3%) had missing information. The 
percentage of men whose Gleason score was 
upgraded (i.e., found to be higher) after radical 
prostatectomy was similar in the MRI-targeted 
biopsy group (5 of 30 men [17%]) and the stan-
dard-biopsy group (4 of 27 [15%]). Details are 
provided in Tables S13 through S15 in the Sup-
plementary Appendix.
Characteristic
MRI-Targeted Biopsy Group 
(N = 252)
Standard-Biopsy Group 
(N = 248)
Age — yr 64.4±7.5 64.5±8.0
PSA level — ng/ml
Median 6.75 6.50
Interquartile range 5.16–9.35 5.14–8.65
Family history of prostate cancer — no. (%) 48 (19) 40 (16)
Abnormal digital rectal examination — no. (%) 36 (14) 38 (15)
*  Plus–minus values are means ±SD. Men who were randomly assigned to the MRI-targeted biopsy group underwent 
MRI. If the MRI revealed results that were suggestive of prostate cancer, the participant underwent a targeted biopsy; 
men whose MRI results were not suggestive of prostate cancer were not offered biopsy. Men who were assigned to the 
standard-biopsy group underwent standard transrectal ultrasonography–guided biopsy. The characteristics of the par-
ticipants at baseline were similar in the two groups. PSA denotes prostate-specific antigen.
Table 1. Characteristics of the Participants at Baseline.*
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Outcome
MRI-Targeted Biopsy 
Group 
(N = 252)
Standard-Biopsy 
Group 
(N = 248) Difference† P Value
Biopsy outcome — no. (%) — —
No biopsy because of negative result on MRI 71 (28) 0
Benign tissue 52 (21) 98 (40)
Atypical small acinar proliferation 0 5 (2)
High-grade prostatic intraepithelial neoplasia 4 (2) 10 (4)
Gleason score
3+3 23 (9) 55 (22)
3+4 52 (21) 35 (14)
3+5 2 (1) 1 (<1)
4+3 18 (7) 19 (8)
4+4 13 (5) 6 (2)
4+5 7 (3) 2 (1)
5+5 3 (1) 1 (<1)
No biopsy‡ 4 (2) 3 (1)
Withdrawal from trial§ 3 (1) 13 (5)
Clinically significant cancer¶
Intention-to-treat analysis — no. (%) 95 (38) 64 (26) 12 (4 to 20) 0.005
Modified intention-to-treat analysis —  
no./total no. (%)
95/245 (39) 64/235 (27) 12 (3 to 20) 0.007
Per-protocol analysis — no./total no. (%) 92/235 (39) 62/227 (27) 12 (3 to 20) 0.007
Clinically insignificant cancer — no. (%) 23 (9) 55 (22) −13 (−19 to −7) <0.001
Maximum cancer core length — mm 7.8±4.1 6.5±4.5 1.0 (0.0 to 2.1) 0.053
Core positive for cancer — no./total no. of cores (%) 422/967 (44) 515/2788 (18) — —
Men who did not undergo biopsy — no. (%)‖ 78 (31) 16 (6) — —
*  Clinically significant cancer was defined as the presence of a single biopsy core indicating disease of Gleason score 3+4 (Gleason sum of 7)  
or greater, and clinically insignificant cancer as a biopsy sample with a Gleason score of 3+3 (Gleason sum of 6). The Gleason score is 
 composed of a primary (most predominant) grade plus a secondary (highest nonpredominant) grade; the range for a primary or secondary 
grade is from 3 to 5, with the Gleason sum ranging from 6 to 10, and with higher scores indicating a more aggressive form of prostate 
 cancer.
†  Differences between rates are shown in percentage points, and the difference in maximum cancer core length is shown in millimeters. 
Differences in the percentages of men with clinically significant cancer detected and men with clinically insignificant cancer were calculated 
with a generalized linear mixed model (with the use of an identity link function with a binomial distribution) that included trial center as a 
random effect. The between-center variance estimates for the intention-to-treat analysis of the proportion of men with clinically significant 
cancer was 0.002 and for the proportion of men with clinically insignificant cancer was 0; the 95% prediction intervals for the detection rates of 
clinically significant and clinically insignificant cancer, incorporating between-center variation, were 14 to 39% and 17 to 28%, respectively, for 
standard biopsy, and 26 to 51% and 4 to 11%, respectively, for MRI-targeted biopsy. The difference in the maximum cancer core length was 
calculated with the use of a linear mixed model with trial center as a random effect. The between-center estimate of variance was 2.14; the 
95% prediction interval for the maximum cancer core length, incorporating between-center variation, was 3.3 to 9.8 mm for standard biopsy 
and 4.4 to 10.8 mm for MRI-targeted biopsy.
‡  In four participants in the MRI-targeted biopsy group, MRI identified at least one area with a score on the Prostate Imaging–Reporting and 
Data System, version 2, of 3 or greater (on a scale from 1 to 5, with higher numbers indicating a greater likelihood of clinically significant 
cancers), but targeted biopsy was not performed. In the standard-biopsy group, three participants declined transrectal ultrasonography–
guided biopsy and underwent an MRI. The MRI revealed no areas that were suggestive of prostate cancer, and the participants did not 
 undergo biopsy.
§  These participants did not complete any diagnostic test.
¶  The intention-to-treat analysis included all the participants who underwent randomization, the modified intention-to-treat analysis excluded 
participants who did not complete a diagnostic test strategy, and the per-protocol analysis included only participants who underwent the 
randomly assigned testing procedure as specified in the protocol.
‖  Data include men who did not undergo biopsy because they withdrew before undergoing any diagnostic test or because they did not com-
plete the diagnostic strategy.
Table 2. Comparison of Cancer Detection between Groups.*
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Quality Control
Results of the quality-control review of multipa-
rametric MRI showed that the percentage of 
cases that were scored with agreement for con-
cordant biopsy decision by the central radiology 
team and the site radiologist was 78% (50 of 64 
cases). The percentage of cases that were scored 
with agreement on the Gleason score by the 
central pathologists and the site pathologist was 
88% (53 of 60 cases). Details are provided in 
Table S16A, S16B, and S16C in the Supplemen-
tary Appendix.
Discussion
The ideal test for prostate cancer would be 
minimally invasive, have few side effects, iden-
tify a high proportion of men who would benefit 
from treatment, and minimize the identification 
of men with clinically insignificant cancer in 
order to prevent overtreatment. In men with a 
clinical suspicion of prostate cancer who had not 
undergone biopsy of the prostate previously, the 
PRECISION trial showed that MRI, with or with-
out targeted biopsy, appeared to achieve these 
goals better than the traditional standard of 
care, transrectal ultrasonography–guided biop-
sy. MRI, with or without targeted biopsy, led to 
fewer men undergoing biopsy, more clinically 
significant cancers being identified, less overde-
tection of clinically insignificant cancer, and 
fewer biopsy cores being obtained than did stan-
dard transrectal ultrasonography–guided biopsy. 
Slightly more than one quarter of the men 
avoided a biopsy altogether, and the 30-day 
participant-reported side-effect profile appeared 
to be more favorable in the MRI-targeted biopsy 
group than in the standard-biopsy group. The 
MRI-targeted biopsy approach was also well ad-
hered to by the participants and clinicians, with 
only 7 of 252 men (3%) not completing the diag-
nostic test strategy (Fig. 1).
The results of single-center studies have been 
mixed. Some studies have not shown the superi-
ority of an MRI-based pathway over transrectal 
ultrasonography–guided biopsy, although these 
comparisons were likely to have been underpow-
ered.12,22 Other single-center studies have shown 
advantages of an MRI-based diagnostic pathway 
over transrectal ultrasonography–guided biop-
sy,13,14,23 and a meta-analysis of published studies 
had findings concordant with those of our tri-
al.15 These single-center studies have limitations 
in their lack of generalizability, and the majority 
of the studies were small and nonrandomized.
The PRECISION trial was an international 
trial, and key strengths included its size and 
pragmatism.24 We did not limit the performance 
of MRI-targeted biopsy to highly experienced 
operators, and most of the participating investi-
gators had modest experience with MRI-targeted 
biopsy, particularly as compared with standard 
Figure 2. Intention-to-Treat, Modified Intention-to-Treat, and Per-Protocol Analyses of the Primary Outcome  
for the Detection of Clinically Significant Prostate Cancer.
Shown are the absolute differences between the MRI-targeted biopsy group and the standard-biopsy group in the 
rates of detection of clinically significant cancer. The intention-to-treat analysis included all the participants who 
 underwent randomization, the modified intention-to-treat analysis excluded participants who did not complete a 
 diagnostic test strategy, and the per-protocol analysis included only participants who underwent the randomly as-
signed testing procedure as specified in the protocol. If the lower boundary of the two-sided 95% confidence inter-
val for the difference (MRI-targeted biopsy group minus standard-biopsy group) was greater than −5 percentage 
points (dashed line), then MRI, with or without targeted biopsy, would be deemed to be noninferior. If the lower 
boundary was greater than zero (solid line), superiority would be claimed.
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transrectal ultrasonography–guided biopsy. We 
also allowed nonacademic centers outside the 
original expert group to take part. In addition, 
either 1.5-T or 3.0-T MRI machines were permit-
ted, and the use of an endorectal coil was per-
mitted but not required. Also, various techniques 
of MRI-targeted biopsy, with visual registration 
or software-assisted registration with either 
transrectal or transperineal access routes, were 
permitted. This approach is supported by a meta-
analysis of studies that showed a lack of supe-
riority of any one registration approach.25 We 
believed that the results would be more gener-
alizable if we permitted centers to use their local 
expertise and resources than if we required that 
they use a particular operating system or access 
route that may not have been available to all 
centers outside of the trial. We observed differ-
ences among centers in the detection of clini-
cally significant cancers. However, on average, 
MRI with or without targeted biopsy was conclu-
sively superior to standard transrectal ultraso-
nography–guided biopsy.
Our trial has limitations. First, despite the 
use of standardized reporting of MRI results,9 
the central quality-control review of multipara-
metric MRIs (Table S16A in the Supplementary 
Appendix) showed moderate agreement (78%) 
between the site and the central radiologist read-
ing, a finding that highlights that there is still 
room for improvement in attaining consistency 
in the reporting of the results of multiparamet-
ric MRI. Regardless, the degree of agreement 
with central interpretation was similar to the 
interrater agreement that has been seen in other 
studies involving expert readers of multipara-
metric MRIs.1,26 This finding highlights the need 
for further research regarding improvements to 
the standardization, reproducibility, and report-
ing of multiparametric MRIs.
Second, a small proportion of the pathologi-
cal test results were upgraded or downgraded on 
central pathological review. However, the differ-
ences were not substantial between groups, and 
the agreement that was seen on central review 
was consistent with that seen in the literature.27
Third, there are concerns about the men with 
negative results on multiparametric MRI who do 
not undergo biopsy. It has been shown that 
these men have a low risk of clinically signifi-
cant cancer,1 but nonetheless, follow-up with 
monitoring of the PSA level is routine, reason-
able, and safe. Participants provided consent for 
long-term follow-up in national registries. More-
over, this trial showed that, among men with 
negative results on initial tests, a far greater 
proportion of the participants in the standard-
biopsy group underwent further diagnostic tests 
than did those in the MRI-targeted biopsy 
group, a finding that confirms that a negative 
result on multiparametric MRI was more reas-
suring to the participants and clinicians than a 
negative result on standard transrectal ultraso-
nography–guided biopsy.
Fourth, it is possible that clinically signifi-
cant cancers may have been missed by the 
omission of standard biopsy cores in men in 
the MRI-targeted biopsy group. Previous well-
designed studies have highlighted that the percent-
age of cases of clinically significant cancer that 
are missed by MRI-targeted biopsy but detected 
by standard transrectal ultrasonography–guided 
Figure 3. Percentages of Men with Clinically Significant, Clinically Insignificant, 
and No Cancer, Identified According to PI-RADS v2 Score.
For men randomly assigned to the MRI-targeted biopsy group, the areas of 
the prostate were scored with the use of the Prostate Imaging–Reporting 
and Data System, version 2 (PI-RADS v2). Scores range from 1 to 5, with 
higher numbers indicating a greater likelihood of clinically significant can-
cer; a score of 3 indicates equivocal results, 4 results that are likely to be 
prostate cancer, and 5 results that are highly likely to be prostate cancer. 
Men who had a score of 3 or higher underwent MRI-targeted biopsy. Clini-
cally significant cancer was defined as the presence of a single biopsy core 
indicating disease of Gleason score 3+4 (Gleason sum of 7) or greater, and 
clinically insignificant cancer as a biopsy sample with a Gleason score of 
3+3 (Gleason sum of 6). The Gleason score is composed of a primary 
(most predominant) grade plus a secondary (highest nonpredominant) 
grade; the range for a primary or secondary grade is from 3 to 5, with the 
Gleason sum ranging from 6 to 10, and with higher scores indicating a 
more aggressive form of prostate cancer. Percentages may not total 100 
because of rounding.
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biopsy is low, between 0% and 10%.12,13,23,28 De-
spite more than one quarter of the men avoiding 
a biopsy, this trial showed that when clinicians 
limited themselves to the use of MRI-targeted 
biopsies only, the rates of detection of clinically 
significant cancer were higher than those seen 
with the standard of care. Furthermore, because 
systematic biopsy was avoided, clinically insig-
nificant cancer was detected in fewer men, 
which may have a substantial benefit in reducing 
the overtreatment of men with prostate cancer. 
If both systematic biopsy and MRI-targeted bi-
opsy were carried out in the same man at the 
same time, the performance of one test could be 
influenced by the other, which would make it 
difficult to evaluate the unbiased performance 
of each test individually.
We acknowledge that the acquisition and re-
porting of MRI of the prostate are specialist 
skills with a learning curve and that the radiolo-
gists involved in this trial were reporting a high 
volume of MRIs per year (median, 300 MRIs per 
year). We suggest that those who report MRIs of 
the prostate report a high volume of scans under 
the supervision of a radiologist who is experi-
enced in MRI of the prostate. We acknowledge 
that a change in the standard of care for pros-
tate-cancer diagnosis would entail changes in 
health care systems to accommodate appropriate 
MRI capacity and to meet the training needs of 
radiologists and urologists. From a health eco-
nomics perspective, the cost savings with MRI, 
with or without targeted biopsy, over standard 
transrectal ultrasonography–guided biopsy may 
emerge from the earlier detection of clinically 
significant cancers, fewer cases of insignificant 
cancer diagnosed, and fewer repeat biopsies. 
Reports from other studies and in different 
contexts suggest that this pathway may be cost-
effective in the long term.29-31
In conclusion, in men with a clinical suspi-
cion of prostate cancer, we found that a diagnos-
tic pathway including risk assessment with MRI 
before biopsy and MRI-targeted biopsy in the 
presence of a lesion suggestive of cancer was 
superior to the diagnostic pathway of standard 
transrectal ultrasonography–guided biopsy.
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